TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34506240
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg/acetaminophen 325 mg every 4 hours as needed for severe pain for 4 days
Study: 34506240
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (codeine and oxycodone)
Study: 35063882
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus concurrent chemoradiotherapy
Study: 35265234
Drug: UTVOR (volatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTVOR (volatile oil of Olibanum and volatile oil of Chuanxiong Rhizoma with ultrasound therapy)
Study: 36197757
Drug: Ozoralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozoralizumab 30 mg and 80 mg
Study: 32048133
Drug: High lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lactate levels (≥ 2 mmol/l)
Study: 32048133
Drug: Low lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lactate levels (< 2 mmol/l)
Study: 33322963
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received directly observed therapy of asthma controller medication, medication adjustments, and daily self-management support.
Study: 34772609
Drug: Chemotherapy (capecitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (capecitabine, oxaliplatin added an investigator's choice)
Study: 33793609
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation with virtual reality using the Wii® console, Wii-Remote and Wii Balance Board, performing balance games for 30 minutes to an hour, twice a week for 10 weeks (total: 20 sessions).
Study: 33793609
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation with virtual reality using the Wii® console, Wii-Remote and Wii Balance Board, performing balance games and muscle strength games for 30 minutes to an hour, twice a week for 10 weeks (total: 20 sessions).
Study: 35949961
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy (8 Hz, 3.2 mT) in addition to a conventional rehabilitation program
Study: 35949961
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation program (physical modalities, exercises, and occupational therapy)
Study: 33078386
Drug: Fenfluramine at
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine at 0.2 mg/kg/d, titrated to a maximum of 0.7 mg/kg/d (or 0.4 mg/kg/d with stiripentol)
Study: 39028916
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy
Study: 34252783
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for youth with co-occurring mental health and substance use concerns
Study: 33977687
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) and Atorvastatin (10 mg) once a day for 8 weeks
Study: 34248001
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel treatment
Study: 35793884
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with western medication
Study: 34279749
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination carteolol/latanoprost (LCFC)
Study: 33941629
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (open reduction and internal fixation)
Study: 32015461
Drug: AVL-3288 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVL-3288 (10 mg)
Study: 32015461
Drug: AVL-3288 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVL-3288 (30 mg)
Study: 36301170
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (acupotomy + warm needling)
Study: 34936267
Drug: Horizontal penetration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horizontal penetration needling at vertigo auditory area and balance area (treatment given once every other day for two courses of treatment)
Study: 34936267
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acupuncture and medication)
Study: 32554067
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg per hour maintenance) with midazolam (0.03 mg/kg)
Study: 32554067
Drug: Propofol (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (125 μg/kg per minute infusion over 10 minutes with intraoperative boluses of 0.1 μg/kg) and fentanyl (0.8 μg/kg) with midazolam (0.03 mg/kg)
Study: 32543980
Drug: Cryotherapy spray
Normalized name: MENTHOL 10.5 g in 100 mL TOPICAL LIQUID [Tidl Full Body Pain Relief Cryotherapy Spray.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy spray (Cryo‐sp)
Study: 32267071
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin analog (BI)
Study: 33616875
Drug: Mid-mixture insulin
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-mixture insulin analog (MMI)
Study: 34051428
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (4 g ALA/day)
Study: 34051428
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g DHA + 0.8 g EPA/day)
Study: 35623756
Drug: Diabetes Community
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes Community Exercise and Education Programme (DCEP) - twice weekly sessions of exercise and education over 12 weeks, followed by ongoing exercise classes.
Study: 35907490
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily dosing of vitamin D
Study: 35907490
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses followed by standard daily dosing of vitamin D
Study: 34423510
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group treated with 30% GA peel at 2 weekly intervals with 5% TXA solution applied twice daily
Study: 35172878
Drug: Treatment holiday
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment holiday (TH) group: belimumab 10 mg/kg IV discontinued for 24 weeks, then restarted 10 mg/kg IV every 4 weeks for 28 weeks
Study: 35172878
Drug: Treatment continuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment continuation (TC) group: continued on belimumab 10 mg/kg IV plus standard therapy every 4 weeks for 52 weeks
Study: 35172878
Drug: Long-term discontinuation
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term discontinuation (LTD) group: permanently withdrawn from further belimumab treatment
Study: 35066982
Drug: EGF-containing cream
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF-containing cream
Study: 33107666
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) - 10 weekly telephone sessions
Study: 33140719
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper limb therapy
Study: 33184771
Drug: Environmental diffusion
Normalized name: LUNG DIFFUSION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental diffusion essential oil therapy (EOT) combined with psychotropic drug therapy (group A)
Study: 33184771
Drug: Psychotropic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drug therapy alone (group B)
Study: 35239778
Drug: Traction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traction therapy
Study: 33401984
Drug: SMOF Lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMOF Lipid 20% infusion
Study: 33755235
Drug: Once-weekly selinexor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly selinexor, bortezomib, and low-dose dexamethasone (XVd)
Study: 33755235
Drug: Standard twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd)
Study: 33152284
Drug: POAI (letrozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: POAI (letrozole 2.5 mg per day or anastrozole 1 mg per day for 14 days)
Study: 38771467
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily for 4 weeks)
Study: 33080002
Drug: Control (non-tocilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-tocilizumab treatment)
Study: 35678062
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) plus Exercise Therapy (ET)
Study: 35678062
Drug: Low-Intensity Pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) plus Exercise Therapy (ET)
Study: 34622567
Drug: liraglutide (≤1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (≤1.8 mg/d)
Study: 34622567
Drug: oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral antidiabetic drug (OAD)
Study: 33726724
Drug: Therapies from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies from CAM providers
Study: 33726724
Drug: CAM therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM therapies from physicians
Study: 34235821
Drug: Drugs
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs
Study: 34001059
Drug: FOLFIRINOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, irinotecan 150–180 mg/m2, 5‐fluorouracil: 400 mg/m2 then 2400 mg/m2 over 46 h) every 14 days with regorafenib (80 to 160 mg, orally, once daily on days 4 to 10 of each cycle)
Study: 32927858
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy + Exercise
Study: 35339280
Drug: Tranilast (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast (300 mg daily) for 7 days
Study: 35339280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antiviral therapy only)
Study: 32644875
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) dose
Study: 32553417
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with conventional side-vented needle irrigation and ultrasonic activation (Control)
Study: 34872102
Drug: Peripheral low‐concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral low‐concentration (10 µg/mL) norepinephrine infusion
Study: 34872102
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 0.9%) infusion
Study: 35659704
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg (ipi3)
Study: 35659704
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg (ipi10)
Study: 36037679
Drug: Milvexian (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (oral small-molecule inhibitor of FXIa)
Study: 36067616
Drug: R +
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: R + L (ribociclib plus letrozole)
Study: 35692220
Drug: Favipiravir +
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir + camostat + ciclesonide combination therapy
Study: 35692220
Drug: Favipiravir monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir monotherapy
Study: 37676977
Drug: Dignity Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity Therapy
Study: 35652769
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 70% alcohol (CPN20 group)
Study: 35652769
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL 70% alcohol (CPN40 group)
Study: 38630551
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks
Study: 35427471
Drug: Chemotherapy (mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab)
Study: 32671687
Drug: FPG level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG level 1 (≤ 5.6 mmol/L)
Study: 32671687
Drug: FPG level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG level 2 (> 5.6 to ≤ 6.1 mmol/L)
Study: 32671687
Drug: FPG level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG level 3 (> 6.1 to ≤ 7.0 mmol/L)
Study: 33597289
Drug: Bimagrumab 10
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 10 mg/kg, 3 mg/kg, 1 mg/kg administered as IV infusions every 4 weeks
Study: 33597289
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as IV infusions every 4 weeks
Study: 33597289
Drug: Bimagrumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab (all doses pooled)
Study: 35583581
Drug: Wen-Luo-Tong Granules
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wen-Luo-Tong Granules (WLT) plus oral Mecobalamin for 1 week
Study: 33727797
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of montelukast sodium chewable tablets
Study: 33727797
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of montelukast sodium chewable tablets
Study: 34500109
Drug: Concurrent anodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent anodal tDCS over M1 and DLPFC
Study: 33902546
Drug: Interactive augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive augmented reality-based telerehabilitation in conjunction with hospital-based physical therapy for 3 months
Study: 33902546
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure) for 3 months
Study: 33902546
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure)
Study: 36460017
Drug: Atezolizumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Study: 36460017
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Study: 36460017
Drug: Atezolizumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib and cobimetinib
Study: 32676959
Drug: Extrapleural autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrapleural autologous blood injection (EPABI) + Intraparenchymal autologous blood patch injection (IABPI), n = 40
Study: 32676959
Drug: Intraparenchymal autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraparenchymal autologous blood patch injection (IABPI) only, n = 41
Study: 35554617
Drug: high/fast: 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: high/fast: 1.0 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Study: 35554617
Drug: high/slow: 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: high/slow: 1.0 mg nicotine delivered over 20 pulsed-infusions
Study: 35554617
Drug: low/fast: 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: low/fast: 0.2 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Study: 35554617
Drug: low/slow: 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: low/slow: 0.2 mg nicotine delivered over 20 pulsed-infusions
Study: 35554617
Drug: placebo: Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: Saline delivered over 20 pulsed-infusions
Study: 35763894
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise program (twice-a-week for 3 months)
Study: 32702363
Drug: Elagolix (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix (300 mg twice a day) with hormonal add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate once a day)
Study: 36027804
Drug: Classical ayurvedic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical ayurvedic pharmaceutical form of herbal medicines
Study: 32562310
Drug: L-EVOO (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-EVOO (250 mg total phenols kg-1 of oil)
Study: 32562310
Drug: M-EVOO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-EVOO (500 mg total phenols kg-1 of oil)
Study: 32562310
Drug: H-EVOO (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-EVOO (750 mg total phenols kg-1 of oil)
Study: 34181712
Drug: 21 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 g/d S. cerevisiae fermentation product (SCFP)
Study: 35551088
Drug: Intervention integrating
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention integrating PGHD with clinician and patient nudges (weekly text-based symptom surveys and passively recorded step counts)
Study: 34397615
Drug: Intraosseous (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous (IO) prophylactic antibiotics
Study: 34397615
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) prophylactic antibiotics
Study: 32224762
Drug: Preventive interventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive interventional therapy for brain AVMs
Study: 32224762
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment for unruptured intracranial aneurysms
Study: 35804346
Drug: Routine maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine maternal and oral health care (Control group, n=200)
Study: 33141921
Drug: Clopidogrel-based DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-based DAPT (600 mg on day 1, 150 mg on days 2-6)
Study: 33141921
Drug: Clopidogrel single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel single antiplatelet therapy (SAPT)
Study: 33183928
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) fluorescence imaging (FI) with 0.25 mg/kg dosage
Study: 32198565
Drug: Concurrent percutaneous
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent percutaneous access during PCNL (group 2)
Study: 32338624
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment and mobile app providing tailored smoking cessation support messages
Study: 32338624
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (psychopharmacological treatment)
Study: 32338624
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to pharmacological therapy
Study: 35451359
Drug: Liver meat
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver meat balls (LMB) supplement, 3 times a week for 90 days
Study: 35451359
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no supplement
Study: 32776698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment and home programmes)
Study: 38733447
Drug: Beta-blocker use
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker use
Study: 35411981
Drug: Drug holidays
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug holidays of more than 11 weeks
Study: 35411981
Drug: Higher infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher infliximab doses
Study: 33677827
Drug: Sulodexide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (oral 1,000 LRU/d) for 21 days
Study: 36424684
Drug: Low-dose indomethacin/levonorgestrel-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose indomethacin/levonorgestrel-releasing intrauterine system
Study: 36424684
Drug: Middle-dose indomethacin/levonorgestrel-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose indomethacin/levonorgestrel-releasing intrauterine system